News Release
1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com
|
|
|
|
News Release |
|
Contact:
Patricia A. Spinella, Investor Relations –
201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369
BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER
Reports third-quarter earnings per share from continuing operations of 95 cents, an increase of 14% from the prior year’s quarter
Raises guidance for full fiscal year 2007 earnings per share from continuing operations to $3.81 to $3.83 from $3.76 to $3.80, excluding specified items
Franklin Lakes, NJ (July 26, 2007) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.631 billion for the third fiscal quarter ended June 30, 2007, representing an increase of 12 percent over the prior year period. This quarter’s growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 3 percentage points of the increase in quarterly revenues.
“We are pleased with our strong results this quarter, with each of our three segments contributing to our growth,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “The combination of solid revenue growth and continued margin improvement is allowing us to increase our investment in innovation while at the same time driving double-digit increases in earnings. These results, along with our expectations for the remainder of fiscal 2007, have enabled us to once again increase our earnings outlook for the year.”
Analysis of Third Quarter and Nine-Month
Periods of Fiscal Year 2007 and 2006 Earnings
Reported diluted earnings per share from continuing
operations were 95 cents for the third quarter of fiscal 2007. The following
analysis (Table 1) of diluted earnings per share from continuing operations
for the third quarters of fiscal 2007 and 2006 identifies specified items that
affect comparability of results between periods. As illustrated, third quarter
fiscal 2007 diluted earnings per share from continuing operations of 98 cents,
which exclude a specified item, increased by 18 percent over comparable third
quarter fiscal 2006 diluted earnings per share from continuing operations of
83 cents. For the nine-month periods, diluted earnings per share from continuing
operations of $2.86 for fiscal 2007, which exclude specified items, increased
by 14 percent over comparable fiscal 2006 diluted earnings per share from continuing
operations of $2.50, which exclude specified items.
| (Table 1) | Three
Months Ended June 30, |
Nine
Months Ended June 30, |
|||||||||||||||||||||||
FY2007 |
FY2006 |
%
Change |
FY2007 |
FY2006 |
%
Change |
||||||||||||||||||||
| Diluted EPS from Continuing Operations: | $ |
0.95 | $ |
0.83 |
14 | % | $ |
2.38 | $ | 2.33 | 2 | % | |||||||||||||
| Specified Items: | |||||||||||||||||||||||||
| In-Process Research and Development Charge | 0.03 | (1) | - |
0.48 | (2) | 0.21 | (2) | ||||||||||||||||||
| Insurance Settlement | - |
- |
- |
(0.04 | ) | (3) | |||||||||||||||||||
| 0.03 | - |
0.48 | 0.17 | ||||||||||||||||||||||
| Diluted EPS from Continuing Operations | |||||||||||||||||||||||||
| Excluding Specified Items: | $ |
0.98 | $ |
0.83 |
18 | % | $ |
2.86 | $ | 2.50 | 14 | % | |||||||||||||
(1) Represents the effect on diluted earnings per share from continuing operations of an in-process research and development (“IPR&D”) charge recorded in the third quarter of fiscal 2007 related to the acquisition of Plasso Technology, Ltd. on May 4, 2007 for approximately $10 million.
(2) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.
(3) Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Company’s previously owned latex glove business.
Segment Results
In the BD Medical segment, worldwide revenues
for the quarter were $882 million, representing an increase of 10 percent
from the prior year period. For the nine-month period ended June 30, 2007,
the BD Medical segment reported 10 percent revenue growth. Strong sales in
the Pharmaceutical Systems unit continued to significantly contribute to the
growth of the segment.
In the BD Diagnostics segment, worldwide revenues for the quarter were $492 million, representing an increase of 15 percent from the prior year’s quarter. This growth includes $27 million of revenues from TriPath, which was acquired at the end of the first quarter of fiscal 2007. The Preanalytical Systems unit of the segment reported revenue growth of 9 percent. Third quarter revenues in the Diagnostic Systems unit of the segment increased 23 percent, again including revenues from the TriPath acquisition. For the nine-month period ended June 30, 2007, the BD Diagnostics segment reported 9 percent revenue growth.
In the BD Biosciences segment, worldwide revenues for the quarter were $258 million, representing an increase of 13 percent from the prior year’s quarter. Flow cytometry instrument and reagent sales, as well as sales of advanced bioprocessing products, contributed to growth. For the nine-month period ended June 30, 2007, the BD Biosciences segment reported 12 percent revenue growth, resulting from continued strong sales of those same products.
Geographic Results
Third quarter revenues in the U.S. were $768
million, representing an increase of 10 percent over the prior year period,
and include $27 million of revenues from TriPath. Revenues outside the
U.S. were $863 million, representing an increase of 13 percent over the
prior year period. Approximately 6 percentage points of the increase in international
revenues resulted from the favorable impact of foreign currency translation.
For the nine-month period ended June 30, 2007, revenues in the U.S. were $2.243 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were $2.466 billion, representing an increase of 10 percent over the prior year period. Approximately 5 percentage points of the increase in international revenues relate to the favorable impact from foreign currency translation.
Fiscal 2007 Outlook for Full Year
The following analysis (Table 2) of estimated
diluted earnings per share from continuing operations for the full fiscal year
identifies specified items that affect the comparability of results between
periods. As illustrated, the Company estimates that diluted earnings per share
from continuing operations, excluding specified items, for the full fiscal
year 2007 will be in the $3.81 to $3.83 range, representing an increase
of approximately 14 to 15 percent over diluted earnings per share from continuing
operations, excluding specified items, of $3.34 for the fiscal year 2006.
| (Table 2) | Twelve
Months Ended |
|||||||||
September
30, |
||||||||||
FY2007 |
FY2006 |
%
Change |
||||||||
(Estimated) |
||||||||||
| Diluted EPS from Continuing Operations: | $3.33-$3.35 | $ | 3.18 | 5 | % | |||||
| Specified Items: | ||||||||||
| In-Process Research and Development Charge(1) | 0.48 | 0.21 | ||||||||
| Insurance Settlement(2) | - | (0.04 | ) | |||||||
| Rounding | - | (0.01 | ) | |||||||
| 0.48 | 0.16 | |||||||||
| Diluted EPS from Continuing Operations | ||||||||||
| Excluding Specified Items: | $3.81-$3.83 | $ | 3.34 | 14%-15 | % | |||||
(1) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.
(2) Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Company’s previously owned latex glove business.
Conference Call Information
A conference call regarding BD’s third fiscal
quarter results and its expectations for the full fiscal year will be broadcast
live on BD’s website, www.bd.com/investors,
at 10:00 a.m. (ET) Thursday, July 26, 2007. The conference call will be available
for replay on BD’s website, www.bd.com/investors,
or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international), using access
code 879048, through the close of business on Thursday, August 2, 2007.
This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.
About BD
BD, a leading global medical technology company
that manufactures and sells medical devices, instrument systems and reagents,
is dedicated to improving people’s health throughout the world. BD is
focused on improving drug therapy, enhancing the quality and speed of diagnosing
infectious diseases, and advancing research and discovery of new drugs and
vaccines. The Company’s capabilities are instrumental in combating many
of the world’s most pressing diseases. Founded in 1897 and headquartered
in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately
50 countries throughout the world. The Company serves healthcare institutions,
life
science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
***
This press release, including the section entitled “Fiscal 2007 Outlook for Full Year,” contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
|
Three Months Ended June 30,
|
|||||||||||
|
2007
|
2006
|
% Change
|
|||||||||
| REVENUES | $ | 1,631,159 | $ | 1,457,347 | 11.9 | ||||||
| Cost of products sold | 791,071 | 719,515 | 9.9 | ||||||||
| Selling and administrative | 412,164 | 374,565 | 10.0 | ||||||||
| Research and development | 92,993 | 76,699 | 21.2 | ||||||||
| Acquired in-process research and development | 7,394 | - | NM | ||||||||
| TOTAL OPERATING COSTS | |||||||||||
| AND EXPENSES | 1,303,622 | 1,170,779 | 11.3 | ||||||||
| OPERATING INCOME | 327,537 | 286,568 | 14.3 | ||||||||
| Interest expense | (11,598 | ) | (15,425 | ) | (24.8 | ) | |||||
| Interest income | 11,938 | 12,146 | (1.7 | ) | |||||||
| Other expense, net | 1,774 | (2,385 | ) | NM | |||||||
| INCOME FROM CONTINUING OPERATIONS BEFORE | |||||||||||
| INCOME TAXES | 329,651 | 280,904 | 17.4 | ||||||||
| Income tax provision | 89,182 | 69,834 | 27.7 | ||||||||
| INCOME FROM CONTINUING OPERATIONS | 240,469 | 211,070 | 13.9 | ||||||||
| INCOME/(LOSS) FROM DISCONTINUED OPERATIONS | |||||||||||
|
NET OF INCOME TAX PROVISION/(BENEFIT) OF
|
|||||||||||
|
$2,704 AND $(2,865),
RESPECTIVELY
|
4,340 | (4,697 | ) | NM | |||||||
| NET INCOME | $ | 244,809 | $ | 206,373 | 18.6 | ||||||
| EARNINGS PER SHARE | |||||||||||
| Basic: | |||||||||||
| Income from continuing operations | $ | 0.98 | $ | 0.86 | 14.0 | ||||||
| Income/(loss) from discontinued operations | $ | 0.02 | $ | (0.02 | ) | NM | |||||
| Net income | $ | 1.00 | $ | 0.84 | 19.0 | ||||||
| Diluted: | |||||||||||
| Income from continuing operations | $ | 0.95 | $ | 0.83 | 14.5 | ||||||
| Income/(loss) from discontinued operations | $ | 0.02 | $ | (0.02 | ) | NM | |||||
| Net income (1) | $ | 0.96 | $ | 0.81 | 18.5 | ||||||
| AVERAGE SHARES OUTSTANDING | |||||||||||
| Basic | 244,918 | 246,633 | |||||||||
| Diluted | 254,128 | 255,070 | |||||||||
NM - Not Meaningful
(1) Total per share amounts may not add due to rounding.
Page 1
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)
2007 |
||||||||||||
As |
Plasso |
Excluding |
||||||||||
Reported |
IPR&D
(1) |
Item |
||||||||||
| Operating Income | $ | 327,537 | $ | 7,394 | $ | 334,931 | ||||||
| as a % of revenues | 20.1 | % | 20.5 | % | ||||||||
| Income from continuing operations | 240,469 | 7,394 | 247,863 | |||||||||
| as a % of revenues | 14.7 | % | 15.2 | % | ||||||||
| Diluted earnings per share | ||||||||||||
| Income from continuing operations | $ | 0.95 | $ | 0.03 | $ | 0.98 | ||||||
(1) Represents the Acquired in-process research and development charge of $7,394 related to the Plasso acquisition.
Page 2
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
|
Nine Months Ended June 30,
|
|||||||||||
|
2007
|
2006
|
% Change
|
|||||||||
| REVENUES | $ | 4,708,607 | $ | 4,275,401 | 10.1 | ||||||
| Cost of products sold | 2,264,544 | 2,084,227 | 8.7 | ||||||||
| Selling and administrative | 1,202,879 | 1,069,914 | 12.4 | ||||||||
| Research and development | 259,620 | 219,473 | 18.3 | ||||||||
| Acquired in-process research and development | 122,133 | 53,300 | NM | ||||||||
| TOTAL OPERATING COSTS | |||||||||||
|
AND EXPENSES
|
3,849,176 | 3,426,914 | 12.3 | ||||||||
| OPERATING INCOME | 859,431 | 848,487 | 1.3 | ||||||||
| Interest expense | (36,152 | ) | (51,990 | ) | (30.5 | ) | |||||
| Interest income | 37,138 | 43,808 | (15.2 | ) | |||||||
| Other expense, net | 5,278 | (3,999 | ) | NM | |||||||
| INCOME FROM CONTINUING OPERATIONS BEFORE | |||||||||||
|
INCOME TAXES
|
865,695 | 836,306 | 3.5 | ||||||||
| Income tax provision | 258,636 | 238,076 | 8.6 | ||||||||
| INCOME FROM CONTINUING OPERATIONS | 607,059 | 598,230 | 1.5 | ||||||||
| INCOME (LOSS) FROM DISCONTINUED OPERATIONS | |||||||||||
|
NET OF INCOME TAX PROVISION/(BENEFIT) OF
|
|||||||||||
|
$14,066 AND $(12,127),
RESPECTIVELY
|
23,162 | (19,929 | ) | NM | |||||||
| NET INCOME | $ | 630,221 | $ | 578,301 | 9.0 | ||||||
| EARNINGS PER SHARE | |||||||||||
| Basic: | |||||||||||
| Income from continuing operations | $ | 2.47 | $ | 2.42 | 2.1 | ||||||
| Income (loss) from discontinued operations | $ | 0.09 | $ | (0.08 | ) | NM | |||||
| Net income (1) | $ | 2.57 | $ | 2.34 | 9.8 | ||||||
| Diluted: | |||||||||||
| Income from continuing operations | $ | 2.38 | $ | 2.33 | 2.1 | ||||||
| Income (loss) from discontinued operations | $ | 0.09 | $ | (0.08 | ) | NM | |||||
| Net income | $ | 2.47 | $ | 2.25 | 9.8 | ||||||
| AVERAGE SHARES OUTSTANDING | |||||||||||
|
Basic
|
245,296 | 247,588 | |||||||||
|
Diluted
|
255,129 | 256,500 | |||||||||
NM - Not Meaningful
(1) Total per share amounts may not add due to rounding.
Page 3
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)
|
2007
|
||||||||||||||||
| As |
TriPath
|
Plasso
|
Excluding
|
|||||||||||||
| Reported |
IPR&D (1)
|
IPR&D (1)
|
Items
|
|||||||||||||
| Operating Income |
$
|
859,431 | $ | 114,739 | $ | 7,394 |
$
|
981,564 | ||||||||
| as a % of revenues | 18.3 | % | 20.8 | % | ||||||||||||
| Income from continuing operations | 607,059 | 114,739 | 7,394 | 729,192 | ||||||||||||
| as a % of revenues | 12.9 | % | 15.5 | % | ||||||||||||
| Diluted earnings per share | ||||||||||||||||
| Income from continuing operations |
$
|
2.38 | $ | 0.45 | $ | 0.03 |
$
|
2.86 | ||||||||
| (1) |
Represents the Acquired in-process research and development charges of $114,739 and $7,394 related to the TriPath and Plasso acquisitions, respectively. |
|
2006
|
||||||||||||||||
| As
|
Insurance
|
GeneOhm
|
Excluding
|
|||||||||||||
|
Reported
|
Settlement (1)
|
IPR&D (2)
|
Items
|
|||||||||||||
| Selling and administrative |
$
|
1,069,914 |
$
|
17,000 | $ |
-
|
$ | 1,086,914 | ||||||||
| as a % of revenues | 25.0 | % | 25.4 | % | ||||||||||||
| Operating Income | 848,487 | (17,000 | ) | 53,300 | 884,787 | |||||||||||
| as a % of revenues | 19.8 | % | 20.7 | % | ||||||||||||
| Income taxes | 238,076 | (6,460 | ) |
-
|
231,616 | |||||||||||
| effective tax rate | 28.5 | % | 26.5 | % | ||||||||||||
| Income from continuing operations | 598,230 | (10,540 | ) | 53,300 | 640,990 | |||||||||||
| as a % of revenues | 14.0 | % | 15.0 | % | ||||||||||||
| Diluted earnings per share | ||||||||||||||||
| Income from continuing operations |
$
|
2.33 |
$
|
(0.04 | ) | $ | 0.21 | $ | 2.50 | |||||||
| (1) |
Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business. |
| (2) |
Represents the Acquired in-process research and development charge of $53,300 related to the GeneOhm acquisition. |
Page 4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
|
Three Months Ended June 30,
|
|||||||||
|
2007
|
2006
|
% Change
|
|||||||
| BD MEDICAL | |||||||||
| United States | $ | 385,546 | $ | 359,146 | 7.4 | ||||
| International | 496,440 | 442,972 | 12.1 | ||||||
| TOTAL | $ | 881,986 | $ | 802,118 | 10.0 | ||||
| BD DIAGNOSTICS | |||||||||
| United States | $ | 272,946 | $ | 233,428 | 16.9 | ||||
| International | 218,579 | 193,511 | 13.0 | ||||||
| TOTAL | $ | 491,525 | $ | 426,939 | 15.1 | ||||
| BD BIOSCIENCES | |||||||||
| United States | $ | 109,593 | $ | 102,547 | 6.9 | ||||
| International | 148,055 | 125,743 | 17.7 | ||||||
| TOTAL | $ | 257,648 | 228,290 | 12.9 | |||||
| TOTAL REVENUES | |||||||||
| United States | $ | 768,085 | $ | 695,121 | 10.5 | ||||
| International | 863,074 | 762,226 | 13.2 | ||||||
| TOTAL | $ | 1,631,159 | $ | 1,457,347 | 11.9 | ||||
Page 5
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
|
Nine Months Ended June 30,
|
|||||||||
|
2007
|
2006
|
% Change
|
|||||||
| BD MEDICAL | |||||||||
| United States | $ | 1,146,143 | $ | 1,056,878 | 8.4 | ||||
| International | 1,406,233 | 1,265,953 | 11.1 | ||||||
| TOTAL | $ | 2,552,376 | $ | 2,322,831 | 9.9 | ||||
| BD DIAGNOSTICS | |||||||||
| United States | $ | 781,644 | $ | 686,728 | 13.8 | ||||
| International | 625,512 | 599,497 | 4.3 | ||||||
| TOTAL | $ | 1,407,156 | $ | 1,286,225 | 9.4 | ||||
| BD BIOSCIENCES | |||||||||
| United States | $ | 314,942 | $ | 291,878 | 7.9 | ||||
| International | 434,133 | 374,467 | 15.9 | ||||||
| TOTAL | $ | 749,075 | $ | 666,345 | 12.4 | ||||
| TOTAL REVENUES | |||||||||
| United States | $ | 2,242,729 | $ | 2,035,484 | 10.2 | ||||
| International | 2,465,878 | 2,239,917 | 10.1 | ||||||
| TOTAL | $ | 4,708,607 | $ | 4,275,401 | 10.1 | ||||
Page 6
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)
|
United States
|
|||||||||
|
2007
|
2006
|
% Change
|
|||||||
| BD MEDICAL | |||||||||
| Medical Surgical Systems | $ | 238,360 | $ | 230,123 | 3.6 | ||||
| Diabetes Care | 92,116 | 88,548 | 4.0 | ||||||
| Pharmaceutical Systems | 48,692 | 34,612 | 40.7 | ||||||
| Ophthalmic Systems | 6,378 | 5,863 | 8.8 | ||||||
| TOTAL | $ | 385,546 | $ | 359,146 | 7.4 | ||||
| BD DIAGNOSTICS | |||||||||
| Preanalytical Systems | $ | 139,572 | $ | 131,909 | 5.8 | ||||
| Diagnostic Systems | 133,374 | 101,519 | 31.4 | ||||||
| TOTAL | $ | 272,946 | $ | 233,428 | 16.9 | ||||
| BD BIOSCIENCES | |||||||||
| Discovery Labware | $ | 37,907 | $ | 35,665 | 6.3 | ||||
| Immunocytometry Systems | 51,234 | 47,027 | 8.9 | ||||||
| Pharmingen | 20,452 | 19,855 | 3.0 | ||||||
| TOTAL | $ | 109,593 | $ | 102,547 | 6.9 | ||||
| TOTAL UNITED STATES | $ | 768,085 | $ | 695,121 | 10.5 | ||||
Page 7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
|
International
|
|||||||||||||
|
% Change
|
|||||||||||||
| 2007 |
2006
|
Reported
|
FX Neutral
|
FX Impact
|
|||||||||
| BD MEDICAL | |||||||||||||
| Medical Surgical Systems |
$
|
233,835 | $ |
217,993 | 7.3 | 1.6 |
5.7
|
||||||
| Diabetes Care | 82,754 | 75,193 | 10.1 | 4.3 |
5.8
|
||||||||
| Pharmaceutical Systems | 168,057 | 139,468 | 20.5 | 12.6 |
7.9
|
||||||||
| Ophthalmic Systems | 11,794 | 10,318 | 14.3 | 7.0 |
7.3
|
||||||||
| TOTAL |
$
|
496,440 | $ |
442,972 | 12.1 | 5.7 |
6.4
|
||||||
| BD DIAGNOSTICS | |||||||||||||
| Preanalytical Systems |
$
|
121,761 | $ |
107,589 | 13.2 | 6.8 |
6.4
|
||||||
| Diagnostic Systems | 96,818 | 85,922 | 12.7 | 7.7 |
5.0
|
||||||||
| TOTAL |
$
|
218,579 | $ |
193,511 | 13.0 | 7.2 |
5.8
|
||||||
| BD BIOSCIENCES | |||||||||||||
| Discovery Labware |
$
|
32,561 | $ |
29,356 | 10.9 | 6.1 |
4.8
|
||||||
| Immunocytometry Systems | 93,331 | 76,947 | 21.3 | 15.5 |
5.8
|
||||||||
| Pharmingen | 22,163 | 19,440 | 14.0 | 8.0 |
6.0
|
||||||||
| TOTAL |
$
|
148,055 | $ |
125,743 | 17.7 | 12.2 |
5.5
|
||||||
| TOTAL INTERNATIONAL |
$
|
863,074 |
$
|
762,226 | 13.2 | 7.1 |
6.1
|
||||||
Page 8
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
|
Total
|
|||||||||||||
|
% Change
|
|||||||||||||
| 2007 |
2006
|
Reported
|
FX Neutral
|
FX Impact
|
|||||||||
| BD MEDICAL | |||||||||||||
| Medical Surgical Systems |
$
|
472,195 | $ | 448,116 | 5.4 | 2.6 |
2.8
|
||||||
| Diabetes Care | 174,870 | 163,741 | 6.8 | 4.2 |
2.6
|
||||||||
| Pharmaceutical Systems | 216,749 | 174,080 | 24.5 | 18.2 |
6.3
|
||||||||
| Ophthalmic Systems | 18,172 | 16,181 | 12.3 | 7.6 |
4.7
|
||||||||
| TOTAL |
$
|
881,986 | 802,118 | 10.0 | 6.4 |
3.6
|
|||||||
| BD DIAGNOSTICS | |||||||||||||
| Preanalytical Systems |
$
|
261,333 | $ | 239,498 | 9.1 | 6.2 |
2.9
|
||||||
| Diagnostic Systems | 230,192 | 187,441 | 22.8 | 20.5 |
2.3
|
||||||||
| TOTAL |
$
|
491,525 | 426,939 | 15.1 | 12.5 |
2.6
|
|||||||
| BD BIOSCIENCES | |||||||||||||
| Discovery Labware |
$
|
70,468 | $ | 65,021 | 8.4 | 6.2 |
2.2
|
||||||
| Immunocytometry Systems | 144,565 | 123,974 | 16.6 | 13.0 |
3.6
|
||||||||
| Pharmingen | 42,615 | 39,295 | 8.4 | 5.5 |
2.9
|
||||||||
| TOTAL |
$
|
257,648 | 228,290 | 12.9 | 9.8 |
3.1
|
|||||||
| TOTAL REVENUES |
$
|
1,631,159 | $ | 1,457,347 | 11.9 | 8.7 |
3.2
|
||||||
Page 9
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)
|
United States
|
|||||||||
|
2007
|
2006
|
% Change
|
|||||||
| BD MEDICAL | |||||||||
| Medical Surgical Systems | $ | 711,545 | $ | 672,438 | 5.8 | ||||
| Diabetes Care | 280,255 | 272,508 | 2.8 | ||||||
| Pharmaceutical Systems | 135,961 | 95,040 | 43.1 | ||||||
| Ophthalmic Systems | 18,382 | 16,892 | 8.8 | ||||||
| TOTAL | $ | 1,146,143 | $ | 1,056,878 | 8.4 | ||||
| BD DIAGNOSTICS | |||||||||
| Preanalytical Systems | $ | 403,211 | $ | 380,110 | 6.1 | ||||
| Diagnostic Systems | 378,433 | 306,618 | 23.4 | ||||||
| TOTAL | $ | 781,644 | $ | 686,728 | 13.8 | ||||
| BD BIOSCIENCES | |||||||||
| Discovery Labware | $ | 109,705 | $ | 100,828 | 8.8 | ||||
| Immunocytometry Systems | 146,684 | 133,691 | 9.7 | ||||||
| Pharmingen | 58,553 | 57,359 | 2.1 | ||||||
| TOTAL | $ | 314,942 | $ | 291,878 | 7.9 | ||||
| TOTAL UNITED STATES | $ | 2,242,729 | $ | 2,035,484 | 10.2 | ||||
Page 10
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
|
International
|
|||||||||||||||
|
% Change
|
|||||||||||||||
| 2007 |
2006
|
Reported
|
FX Neutral
|
FX Impact
|
|||||||||||
| BD MEDICAL | |||||||||||||||
| Medical Surgical Systems | $ | 675,741 | $ | 628,421 | 7.5 | 3.0 |
4.5
|
||||||||
| Diabetes Care | 234,491 | 217,899 | 7.6 | 2.9 |
4.7
|
||||||||||
| Pharmaceutical Systems | 462,540 | 389,912 | 18.6 | 11.5 |
7.1
|
||||||||||
| Ophthalmic Systems | 33,461 | 29,721 | 12.6 | 6.0 |
6.6
|
||||||||||
| TOTAL | $ | 1,406,233 | $ | 1,265,953 | 11.1 | 5.7 |
5.4
|
||||||||
| BD DIAGNOSTICS | |||||||||||||||
| Preanalytical Systems | $ | 342,941 | $ | 308,413 | 11.2 | 5.7 |
5.5
|
||||||||
| Diagnostic Systems | 282,571 | 291,084 | (2.9 | ) | (6.4 | ) |
3.5
|
||||||||
| TOTAL | $ | 625,512 | $ | 599,497 | 4.3 | (0.2 | ) |
4.5
|
|||||||
| BD BIOSCIENCES | |||||||||||||||
| Discovery Labware | $ | 94,987 | $ | 87,279 | 8.8 | 4.8 |
4.0
|
||||||||
| Immunocytometry Systems | 272,082 | 226,709 | 20.0 | 14.9 |
5.1
|
||||||||||
| Pharmingen | 67,064 | 60,479 | 10.9 | 6.2 |
4.7
|
||||||||||
| TOTAL | $ | 434,133 | $ | 374,467 | 15.9 | 11.1 |
4.8
|
||||||||
| TOTAL INTERNATIONAL |
$
|
2,465,878 | $ | 2,239,917 | 10.1 | 5.0 |
5.1
|
||||||||
Page 11
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
|
Total
|
|||||||||||||
|
% Change
|
|||||||||||||
| 2007 |
2006
|
Reported
|
FX Neutral
|
FX Impact
|
|||||||||
| BD MEDICAL | |||||||||||||
| Medical Surgical Systems | $ | 1,387,286 | $ | 1,300,859 | 6.6 | 4.5 |
2.1
|
||||||
| Diabetes Care | 514,746 | 490,407 | 5.0 | 2.9 |
2.1
|
||||||||
| Pharmaceutical Systems | 598,501 | 484,952 | 23.4 | 17.7 |
5.7
|
||||||||
| Ophthalmic Systems | 51,843 | 46,613 | 11.2 | 7.0 |
4.2
|
||||||||
| TOTAL | $ | 2,552,376 | $ | 2,322,831 | 9.9 | 6.9 |
3.0
|
||||||
| BD DIAGNOSTICS | |||||||||||||
| Preanalytical Systems | $ | 746,152 | $ | 688,523 | 8.4 | 5.9 |
2.5
|
||||||
| Diagnostic Systems | 661,004 | 597,702 | 10.6 | 8.9 |
1.7
|
||||||||
| TOTAL | $ | 1,407,156 | $ | 1,286,225 | 9.4 | 7.3 |
2.1
|
||||||
| BD BIOSCIENCES | |||||||||||||
| Discovery Labware | $ | 204,692 | $ | 188,107 | 8.8 | 7.0 |
1.8
|
||||||
| Immunocytometry Systems | 418,766 | 360,400 | 16.2 | 13.0 |
3.2
|
||||||||
| Pharmingen | 125,617 | 117,838 | 6.6 | 4.2 |
2.4
|
||||||||
| TOTAL | $ | 749,075 | $ | 666,345 | 12.4 | 9.7 |
2.7
|
||||||
| TOTAL REVENUES |
$
|
4,708,607 | $ | 4,275,401 | 10.1 | 7.5 |
2.6
|
||||||
Page 12